Guobang Pharma Ltd (605507) - Total Assets
Based on the latest financial reports, Guobang Pharma Ltd (605507) holds total assets worth CN¥11.40 Billion CNY (≈ $1.67 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Guobang Pharma Ltd to assess how comfortably operating cash covers total debt obligations.
Guobang Pharma Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Guobang Pharma Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of Guobang Pharma Ltd for net asset value and shareholders' equity analysis.
Guobang Pharma Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Guobang Pharma Ltd's total assets of CN¥11.40 Billion consist of 55.7% current assets and 44.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.3% |
| Accounts Receivable | CN¥859.33 Million | 7.8% |
| Inventory | CN¥1.78 Billion | 16.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥342.65 Million | 3.1% |
| Goodwill | CN¥25.49K | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Guobang Pharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 605507 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guobang Pharma Ltd's current assets represent 55.7% of total assets in 2025, a decrease from 60.3% in 2017.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 23.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 16.2% of total assets.
Guobang Pharma Ltd Competitors by Total Assets
Key competitors of Guobang Pharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
JW Pharmaceutical Corp
KO:001067
|
Korea | ₩611.56 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
|
China | CN¥4.30 Billion |
|
Fuan Pharmaceutical Group Co
SHE:300194
|
China | CN¥5.97 Billion |
|
DRI Healthcare Trust
TO:DHT-U
|
Canada | $967.26 Million |
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
China | CN¥816.14 Million |
Guobang Pharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.54 | 2.51 | 1.72 |
| Quick Ratio | 1.86 | 1.93 | 1.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.96 Billion | CN¥3.77 Billion | CN¥1.12 Billion |
Guobang Pharma Ltd - Advanced Valuation Insights
This section examines the relationship between Guobang Pharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.49 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | CN¥10.98 Billion |
| Market Capitalization | $1.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Guobang Pharma Ltd's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guobang Pharma Ltd's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guobang Pharma Ltd (2017–2025)
The table below shows the annual total assets of Guobang Pharma Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥10.98 Billion ≈ $1.61 Billion |
+1.89% |
| 2024-12-31 | CN¥10.78 Billion ≈ $1.58 Billion |
+4.04% |
| 2023-12-31 | CN¥10.36 Billion ≈ $1.52 Billion |
+14.58% |
| 2022-12-31 | CN¥9.04 Billion ≈ $1.32 Billion |
+20.37% |
| 2021-12-31 | CN¥7.51 Billion ≈ $1.10 Billion |
+36.39% |
| 2020-12-31 | CN¥5.51 Billion ≈ $806.08 Million |
+15.74% |
| 2019-12-31 | CN¥4.76 Billion ≈ $696.45 Million |
+8.99% |
| 2018-12-31 | CN¥4.37 Billion ≈ $638.98 Million |
+8.51% |
| 2017-12-31 | CN¥4.02 Billion ≈ $588.86 Million |
-- |
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more